863 results on '"Tomii, Keisuke"'
Search Results
2. A randomized double-blind placebo-controlled trial of an inhibitor of plasminogen activator inhibitor-1 (TM5614) in mild to moderate COVID-19
3. Prognostic impact of cytokines and chemokines in bronchoalveolar lavage fluid on acute exacerbation of fibrosing interstitial lung disease
4. Pulmonary function and chest CT abnormalities 3 months after discharge from COVID-19, 2020–2021: A nation-wide multicenter prospective cohort study from the Japanese respiratory society
5. Burden of Uncontrolled Severe Asthma With and Without Elevated Type-2 Inflammatory Biomarkers
6. Reliability of the respiratory rate and oxygenation index for successful high-flow nasal cannula support in coronavirus disease pneumonia: a retrospective cohort study
7. Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
8. Development of a new HISCL automated CXCL9 immunoassay
9. Sputum microbiota and inflammatory subtypes in asthma, COPD, and its overlap
10. Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence
11. Clinical Impact of Pre-Existing Autoantibodies in Patients With SCLC Treated With Immune Checkpoint Inhibitor: A Multicenter Prospective Observational Study
12. Cluster Analyses From the Real-World NOVELTY Study: Six Clusters Across the Asthma-COPD Spectrum
13. Exploratory phase 2 study of the novel oral multi-kinase inhibitor TAS-115 in patients with idiopathic pulmonary fibrosis
14. Predictive factors and clinical impact of ICU-acquired weakness on functional disability in mechanically ventilated patients with COVID-19
15. Mechanical ventilation for acute exacerbation of fibrosing interstitial lung diseases
16. Longitudinal changes in mental health outcomes after COVID-19 hospitalization: A prospective study
17. Clinical outcomes of COVID-19 caused by the Alpha variant compared with one by wild type in Kobe, Japan. A multi-center nested case-control study
18. Risk stratification and prognosis prediction using cardiac biomarkers in COVID-19: a single-centre retrospective cohort study
19. Patient-centered outcomes at hospital discharge in mechanically ventilated COVID-19 patients in Kobe, Japan: A single-center retrospective cohort study
20. The burden of mild asthma: Clinical burden and healthcare resource utilisation in the NOVELTY study
21. Frequent productive cough: Symptom burden and future exacerbation risk among patients with asthma and/or COPD in the NOVELTY study
22. Association between 25-hydroxyvitamin D levels and COVID-19 severity
23. Ringed fluorodeoxyglucose uptake predicted poor prognosis after resection of pulmonary pleomorphic carcinoma
24. End-of-life care for idiopathic pulmonary fibrosis patients with acute exacerbation
25. The prognostic factors of in-hospital death among patients with pneumonic COPD acute exacerbation
26. Successful intracranial response of lorlatinib after resistance with alectinib and brigatinib in patients with ALK‐positive lung adenocarcinoma: Implications of CNS penetration rate of brigatinib.
27. Population Pharmacokinetics of Nivolumab in Japanese Patients with Nonsmall Cell Lung Cancer
28. Phase II Clinical Trial of Combination Therapy with Favipiravir and Methylprednisolone for COVID-19 with Non-Critical Respiratory Failure
29. An additional mechanism enhancing exercise tolerance in interstitial lung disease with high‐flow nasal cannula
30. A rare case of tumor‐to‐tumor metastasis from thymic carcinoma to an ovarian mature teratoma
31. Prognostic Factors for Discharge Directly Home in Patients With Thoracoscopic Surgery for Empyema: A Multicenter Retrospective Cohort Study
32. Long-Term Efficacy of Immune Checkpoint Inhibitor for Squamous Cell Carcinoma Lesion Transformed From EGFR-Mutated Adenocarcinoma After Osimertinib Treatment: A Case Report
33. Estimation of seroprevalence of novel coronavirus disease (COVID-19) using preserved serum at an outpatient setting in Kobe, Japan: A cross-sectional study
34. Dissociated response and clinical benefit in patients treated with nivolumab monotherapy
35. Associated characteristics and treatment outcomes of medication-related osteonecrosis of the jaw in patients receiving denosumab or zoledronic acid for bone metastases
36. Population Pharmacokinetics of Nivolumab in Japanese Patients with Non-Small Cell Lung Cancer
37. Characteristics of interstitial lung disease in patients from post-marketing data on metastatic breast cancer patients who received abemaciclib in Japan
38. Clinical characteristics and outcomes of critically ill patients with COVID-19 in Kobe, Japan: a single-center, retrospective, observational study
39. Anti-transcriptional intermediary factor 1-γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report
40. Association Between Early Immune-related Adverse Events and Clinical Outcomes in Patients With Non–Small Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
41. Unmarked R2 manuscript Sputum microbiota and inflammatory subtypes in asthma, COPD, and its overlap
42. MO2-7 A multicenter prospective observational study of pre-existing autoantibodies in patients with small-cell lung cancer treated with ICI
43. Cutaneous T-cell-attracting chemokine as a novel biomarker for predicting prognosis of idiopathic pulmonary fibrosis: a prospective observational study
44. Genetic determinants of risk in autoimmune pulmonary alveolar proteinosis
45. Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study
46. Effectiveness of empirical anti-pseudomonal antibiotics for recurrent COPD exacerbation: a multicenter retrospective cohort study
47. Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
48. Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia
49. Early depth of tumor shrinkage and treatment outcomes in non-small cell lung cancer treated using Nivolumab
50. Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.